





















The interaction in terms of affinity, association and dissociation constant, and the stability of protein adsorbed were analyzed by using a plenty of techniques including isothermal titration calorimetry (ITC), circular dichroism, surface plasmon resonance, quartz crystal microbalance frequently combined together. Gel filtration has been proposed not only to separate the protein-NP complexes in incubation media as previously reported, but also to isolate proteins from the NP surfaces as well as to provide useful information on kinetic exchange rates for adsorbed proteins [58].

Besides proof of the PC-NPs complex presence, defining the PC represents a major topic: several researchers reported the use of electrophoresis as the preferred technology, while protein *quantity determination* was proposed to be characterized by mass spectrometry, in which protein samples were digested into small peptides and simply injected into the analysis instrument [73].

In summary, as evident, the identification and characterization of the PC cannot be obtained by a single analytical protocol, but different and complementary technologies are generally combined. In order to reach the highest level of quality and standardization in PC identification and characterization, the key point relies on the choice of the techniques in function of both the type of nanocarriers and on the analytical parameter to investigate. Using multiple characterization techniques is therefore crucial to analyze different aspects of the PC (i.e., presence of complex, composition of PC, reliability in *in vivo* conditions, etc.) and to get a better understanding of this biological entity. Remarkably, some techniques allow to detect the protein corona *in situ* (ITC), while other procedures require the detachment of bound proteins from the nanocarriers before measurements, thus still representing a controversial issue on PC analysis, since the adoption of purification methods may change equilibrium properties of the PC.

## CONCLUSION

In recent years, the advance of nanomedicine as applied science in disease treatments highlighted a deeper need in understanding the interactions between nanocarriers and the biological environment aiming to improve their effectiveness and safety profiles. In this context, the study of the PC connected to any kind of NP drug carrier and its impact on both biodistribution and interaction with the target site is of extreme importance. Relevant information of the PC composition could also be exploited in sample screening at early research stages. This interest generated a wide number of attempted experiments, but at a deeper analysis of the results, even if remarkable, the lack of reproducibility and defined protocols in PC analysis still remain an urgent issue. In particular, as pointed out in this brief review, those data often obtained *in vitro* by simulating biological environments are affected by a high number of variables and

seem not to be reliable and predictive for *in vivo* readouts and therefore their translatability. As also pointed out, numerous purification and investigation techniques were applied to evaluate and characterize the PC demonstrating that some technologies could really be useful in analysing some aspects of PC. Thus, in order to concretely exploit PC-NPs complexes data, the scientific path in this field will surely pass through an optimization of the protocols with a rational combination of the different techniques to finalize a systematic and more reproducible PC study approach.

## ACKNOWLEDGEMENT

Supported by MAECI grant (PI Tosi, Nanomedicine for BBB-crossing in CNS oncologic pathologies) and Emilia Romagna Region grant (Step-by-step screening: RCUP E56C18002000002).

## REFERENCES

1. Bamrungsap S, Zhao Z, Chen T, Wang L, Li C, et al. (2012) Nanotechnology in therapeutics: A focus on nanoparticles as a drug delivery system. *Nanomedicine* 7: 1253-1271.
2. Fornaguera C, Garcia-Celma MJ (2017) Personalized nanomedicine: A revolution at the nanoscale. *J Pers Med* 7.
3. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H (2012) Nanoparticles as drug delivery systems. *Pharmacol Rep* 64: 1020-1037.
4. Knop K, Hoogenboom R, Fischer D, Schubert US (2010) Poly(ethylene glycol) in drug delivery: Pros and cons as well as potential alternatives. *Angewandte Chemie Int* 49: 6288-6308.
5. Friedman AD, Claypool SE, Liu R (2013) The smart targeting of nanoparticles. *Curr Pharm Design* 19: 6315-6329.
6. Pederzoli F, Tosi G, Vandelli MA, Belletti D, Forni F, et al. (2017) Protein corona and nanoparticles: How can we investigate on? *Wiley Interdiscip Rev Nanomed Nanobiotechnol* 9: e1467.
7. Milani S, Bombelli FB, Pitek AS, Dawson KA, Rädler J (2012) Reversible versus irreversible binding of transferrin to polystyrene nanoparticles: Soft and hard corona. *ACS Nano* 6: 2532-2541.
8. Monopoli MP, Aberg C, Salvati A, Dawson KA (2012) Biomolecular coronas provide the biological identity of nanosized materials. *Nat Nanotechnol* 7: 779-786.
9. Sharifi S, Behzadi S, Laurent S, Forrest ML, Stroeve P, et al. (2012) Toxicity of nanomaterials. *Chem Soc Rev* 41: 2323-2343.
10. Mahmoudi M, Lynch I, Ejtehadi MR, Monopoli MP, Bombelli FB, et al. (2011) Protein-nanoparticle

- interactions: Opportunities and challenges. *Chem Rev* 111: 5610-5637.
11. Mao HY, Laurent S, Chen W, Akhavan O, Imani M, et al. (2013) Graphene: Promises, facts, opportunities and challenges in nanomedicine. *Chem Rev* 113: 3407-3424.
  12. Hajipour MJ, Raheb J, Akhavan O, Arjmand S, Mashinchian O, et al. (2015) Personalized disease-specific protein corona influences the therapeutic impact of graphene oxide. *Nanoscale* 7: 8978-8994.
  13. Ogawara K, Furumoto K, Nagayama S, Minato K, Higaki K, et al. (2004) Pre-coating with serum albumin reduces receptor-mediated hepatic disposition of polystyrene nanosphere: Implications for rational design of nanoparticles. *J Control Release* 100: 451-455.
  14. Nagayama S, Ogawara K, Minato K, Fukuoka Y, Takakura Y, et al. (2007) Fetuin mediates hepatic uptake of negatively charged nanoparticles via scavenger receptor. *Int J Pharm* 329: 192-198.
  15. Su G, Jiang H, Xu B, Yu Y, Chen X (2018) Effects of protein corona on active and passive targeting of cyclic RGD peptide-functionalized pegylation nanoparticles. *Mol Pharm* 15: 5019-5030.
  16. Dai Q, Yan Y, Ang CS, Kempe K, Kamphuis MM, et al. (2015) Monoclonal antibody-functionalized multilayered particles: Targeting cancer cells in the presence of protein coronas. *ACS Nano* 9: 2876-2885.
  17. Sun D, Gong L, Xie J, Gu X, Li Y, et al. (2018) Toxicity of silicon dioxide nanoparticles with varying sizes on the cornea and protein corona as a strategy for therapy. *Sci Bull* 63: 907-916.
  18. Deng ZJ, Liang M, Monteiro M, Toth I, Minchin RF (2011) Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. *Nat Nanotechnol* 6: 39-44.
  19. Yan Y, Gause KT, Kamphuis MMJ, Ang CS, O'Brien-Simpson NM, et al. (2013) Differential roles of the protein corona in the cellular uptake of nanoporous polymer particles by monocyte and macrophage cell lines. *ACS Nano* 7: 10960-10970.
  20. Thiele L, Diederichs JE, Reszka R, Merkle HP, Walter E (2003) Competitive adsorption of serum proteins at microparticles affects phagocytosis by dendritic cells. *Biomaterials* 24: 1409-1418.
  21. Borgognoni CF, Mormann M, Qu Y, Schafer M, Langer K, et al. (2015) Reaction of human macrophages on protein corona covered TiO<sub>2</sub> nanoparticles. *Nanomedicine* 11: 275-282.
  22. Schöttler S, Becker G, Winzen S, Steinbach T, Mohr K, et al. (2016) Protein adsorption is required for stealth effect of poly(ethylene glycol)-and poly(phosphoester)-coated nanocarriers. *Nat Nanotechnol* 11: 372-377.
  23. Pochert A, Vernikouskaya I, Pascher F, Rasche V, Linden M (2017) Cargo-influences on the biodistribution of hollow mesoporous silica nanoparticles as studied by quantitative (19)F-magnetic resonance imaging. *J Colloid Interface Sci* 488: 1-9.
  24. De Paoli SH, Diduch LL, Tegegn TZ, Orecna M, Strader MB, et al. (2014) The effect of protein corona composition on the interaction of carbon nanotubes with human blood platelets. *Biomaterials* 35: 6182-6194.
  25. Shi J, Hedberg Y, Lundin M, Odnevall Wallinder I, Karlsson H, et al. (2012) Hemolytic properties of synthetic nano and porous silica particles: The effect of surface properties and the protection by the plasma corona. *Acta Biomater* 8: 3478-3490.
  26. Salvati E, Re F, Sesana S, Cambianica I, Sancini G, et al. (2013) Liposomes functionalized to overcome the blood-brain barrier and to target amyloid-beta peptide: The chemical design affects the permeability across an in vitro model. *Int J Nanomed* 8: 1749-1758.
  27. Varnamkhasti BS, Hosseinzadeh H, Azhdarzadeh M, Vafaei SY, Esfandyari-Manesh M, et al. (2015) Protein corona hampers targeting potential of MUC1 aptamer functionalized SN-38 core-shell nanoparticles. *Int J Pharm* 494: 430-444.
  28. Caracciolo G, Palchetti S, Digiaco L, Chiozzi RZZ, Capriotti AL, et al. (2018) Human biomolecular corona of liposomal doxorubicin: The overlooked factor in anticancer drug delivery. *ACS Appl Mater Interfaces* 10: 22951-22962.
  29. Catalano F, Accomasso L, Alberto G, Gallina C, Raimondo S, et al. (2015) Factors ruling the uptake of silica nanoparticles by mesenchymal stem cells: Agglomeration versus dispersions, absence versus presence of serum proteins. *Small* 11: 2919-2928.
  30. Lesniak A, Fenaroli F, Monopoli MP, Aberg C, Dawson KA, et al. (2012) Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells. *ACS Nano* 6: 5845-5857.
  31. Palchetti S, Caputo D, Digiaco L, Capriotti AL, Coppola R, et al. (2019) Protein corona fingerprints of liposomes: New opportunities for targeted drug delivery and early detection in pancreatic cancer. *Pharmaceutics* 11.
  32. Ge C, Du J, Zhao L, Wang L, Liu Y, et al. (2011) Binding of blood proteins to carbon nanotubes reduces cytotoxicity. *Proc Natl Acad Sci U S A* 108: 16968-16973.

33. Behzadi S, Serpooshan V, Sakhtianchi R, Muller B, Landfester K, et al. (2014) Protein corona change the drug release profile of nanocarriers: The “overlooked” factor at the nanobiointerface. *Colloids Surf B Biointerfaces* 123:143-149.
34. Sempf K, Arrey T, Gelperina S, Schorge T, Meyer B, et al. (2013) Adsorption of plasma proteins on uncoated PLGA nanoparticles. *Eur J Pharm Biopharm* 85: 53-60.
35. Walkey CD, Chan WC (2012) Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. *Chem Soc Rev* 41: 2780-2799.
36. Carrillo-Carrion C, Carril M, Parak WJ (2017) Techniques for the experimental investigation of the protein corona. *Curr Opin Biotechnol* 46: 106-113.
37. Di Silvio D, Rigby N, Bajka B, Mayes A, Mackie A, et al. (2015) Technical tip: High-resolution isolation of nanoparticle-protein corona complexes from physiological fluids. *Nanoscale* 7: 11980-11990.
38. Casals E, Pfaller T, Duschl A, Oostingh GJ, Puntès V (2010) Time evolution of the nanoparticle protein corona. *ACS Nano* 4: 3623-3632.
39. Lundqvist M, Stigler J, Cedervall T, Berggard T, Flanagan MB, et al. (2011) The evolution of the protein corona around nanoparticles: A test study. *ACS Nano* 5: 7503-7509.
40. Monopoli MP, Pitek AS, Lynch I, Dawson KA (2013) Formation and characterization of the nanoparticle-protein corona. *Methods Mol Biol* 1025: 137-55.
41. Walczyk D, Bombelli FB, Monopoli MP, Lynch I, Dawson KA (2010) What the cell “sees” in bionanoscience? *J Am Chem Soc* 132: 5761-5768.
42. Lynch I, Cedervall T, Lundqvist M, Cabaleiro-Lago C, Linse S, et al. (2007) The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. *Adv Colloid Interface Sci* 31: 167-174.
43. Cedervall T, Lynch I, Foy M, Berggard T, Donnelly SC, et al. (2007) Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. *Angew Chem Int Ed Engl* 46: 5754-5756.
44. Ashby J, Pan S, Zhong W (2014) Size and surface functionalization of iron oxide nanoparticles influence the composition and dynamic nature of their protein corona. *ACS Appl Mater Interfaces* 6: 15412-15419.
45. Sakulku U, Mahmoudi M, Maurizi L, Salaklang J, Hofmann H (2014) Protein corona composition of superparamagnetic iron oxide nanoparticles with various physico-chemical properties and coatings. *Sci Rep* 4: 5020.
46. Lundqvist M, Augustsson C, Lilja M, Lundkvist K, Dahlback B, et al. (2017) The nanoparticle protein corona formed in human blood or human blood fractions. *PLoS One* 12.
47. Hadjidemetriou M, Al-Ahmady Z, Kostarelos K (2016) Time-evolution of *in vivo* protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles. *Nanoscale* 8: 6948-6957.
48. Monopoli MP, Walczyk D, Campbell A, Elia G, Lynch I, et al. (2011) Physical-chemical aspects of protein corona: Relevance to *in vitro* and *in vivo* biological impacts of nanoparticles. *J Am Chem Soc* 133: 2525-2534.
49. Maiorano G, Sabella S, Sorce B, Brunetti V, Malvindi MA, et al. (2010) Effects of cell culture media on the dynamic formation of protein-nanoparticle complexes and influence on the cellular response. *ACS Nano* 4: 7481-7491.
50. Mahmoudi M, Abdelmonem AM, Behzadi S, Clement JH, Dutz S, et al. (2013) Temperature: The “ignored” factor at the nanobio interface. *ACS Nano* 7: 6555-6562.
51. Gessner A, Lieske A, Paulke BR, Müller RH (2003) Functional groups on polystyrene model nanoparticles: Influence on protein adsorption. *J Biomed Mater Res Part A* 65: 319-326.
52. Goppert TM, Muller RH (2005) Protein adsorption patterns on poloxamer and poloxamine-stabilized solid lipid nanoparticles (SLN). *Eur J Pharm Biopharm* 60: 361-72.
53. Sohaebuddin SK, Thevenot PT, Baker D, Eaton JW, Tang L (2010) Nanomaterial cytotoxicity is composition, size and cell type dependent. *Particle Fibre Toxicol* 7: 1-22.
54. Arvizo RR, Giri K, Moyano D, Miranda OR, Madden B, et al. (2012) Identifying new therapeutic targets via modulation of protein corona formation by engineered nanoparticles. *PLoS One* 7.
55. Mbeh DA, Javanbakht T, Tabet L, Merhi Y, Maghni K, et al. (2015) Protein corona formation on magnetite nanoparticles: Effects of culture medium composition and its consequences on super paramagnetic nanoparticle cytotoxicity. *J Biomed Nanotechnol* 11: 828-840.
56. Clemments AM, Botella P, Landry CC (2015) Protein adsorption from biofluids on silica nanoparticles: Corona analysis as a function of particle diameter and porosity. *ACS Appl Mater Interfaces* 7: 21682-21689.

57. Nienhaus GU, Maffre P, Nienhaus K (2013) Studying the protein corona on nanoparticles by FCS. *Methods Enzymol* 519: 115-137.
58. Cedervall T, Lynch I, Lindman S, Berggard T, Thulin E, et al. (2007) Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. *Proc Natl Acad Sci U S A* 104: 2050-2055.
59. Winzen S, Schoettler S, Baier G, Rosenauer C, Mailaender V, et al. (2015) Complementary analysis of the hard and soft protein corona: Sample preparation critically affects corona composition. *Nanoscale* 7: 2992-3001.
60. Kaufman ED, Belyea J, Johnson MC, Nicholson ZM, Ricks JL, et al. (2007) Probing protein adsorption onto mercaptoundecanoic acid stabilized gold nanoparticles and surfaces by quartz crystal microbalance and  $\zeta$ -potential measurements. *Langmuir* 23: 6053-6062.
61. Fleischer CC, Payne CK (2014) Nanoparticle-cell interactions: Molecular structure of the protein corona and cellular outcomes. *Acc Chem Res* 47: 2651-2659.
62. Yallapu MM, Chauhan N, Othman SF, Khalilzad-Sharghi V, Ebeling MC, et al. (2015) Implications of protein corona on physico-chemical and biological properties of magnetic nanoparticles. *Biomaterials* 46: 1-12.
63. Ding HM, Ma YQ (2014) Computer simulation of the role of protein corona in cellular delivery of nanoparticles. *Biomaterials* 35: 8703-8710.
64. Mahmoudi M, Shokrgozar MA, Sardari S, Moghadam MK, Vali H, et al. (2011) Irreversible changes in protein conformation due to interaction with superparamagnetic iron oxide nanoparticles. *Nanoscale* 3: 1127-1138.
65. Lundqvist M, Sethson I, Jonsson BH (2004) Protein adsorption onto silica nanoparticles: Conformational changes depend on the particles' curvature and the protein stability. *Langmuir* 20: 10639-10647.
66. Brandes N, Welzel PB, Werner C, Kroh LW (2006) Adsorption-induced conformational changes of proteins onto ceramic particles: Differential scanning calorimetry and FTIR analysis. *J Colloid Interface Sci* 299: 56-69.
67. Gessner A, Lieske A, Paulke BR, Müller R (2002) Influence of surface charge density on protein adsorption on polymeric nanoparticles: Analysis by two-dimensional electrophoresis. *Eur J Pharm Biopharm* 54: 165-170.
68. Göppert TM, Müller RH (2005) Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns. *J Drug Target* 13: 179-187.
69. Pozzi D, Caracciolo G, Capriotti AL, Cavaliere C, La Barbera G, et al. (2015) Surface chemistry and serum type both determine the nanoparticle-protein corona. *J Proteomics* 119: 209-217.
70. Tenzer S, Docter D, Rosfa S, Wlodarski A, Kuharev JR, et al. (2011) Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: A comprehensive quantitative proteomic analysis. *ACS Nano* 5: 7155-7167.
71. Docter D, Distler U, Storck W, Kuharev J, Wunsch D, et al. (2014) Quantitative profiling of the protein coronas that form around nanoparticles. *Nat Protoc* 9: 2030-2044.
72. Pederzoli F, Tosi G, Genovese F, Belletti D, Vandelli Ma, et al. (2018) Qualitative and semi quantitative analysis of the protein coronas associated to different functionalized nanoparticles. *Nanomedicine (Lond)* 13: 407-422.
73. Nguyen VH, Lee BJ (2017) Protein corona: A new approach for nanomedicine design. *Int J Nanomed* 12: 3137-3151.